These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 33116678)

  • 1. Economic Burden of Patients with Bloodstream Infections Caused by Extended-Spectrum β-Lactamase-Producing
    Wang Y; Xiao T; Zhu Y; Ye J; Yang K; Luo Q; Shen P; Xiao Y
    Infect Drug Resist; 2020; 13():3583-3592. PubMed ID: 33116678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Costs and length of stay associated with extended-spectrum β-lactamase production in cases of Escherichia coli bloodstream infection.
    Leistner R; Bloch A; Sakellariou C; Gastmeier P; Schwab F
    J Glob Antimicrob Resist; 2014 Jun; 2(2):107-109. PubMed ID: 27873587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Retrospective Analysis of Risk Factors and Patient Outcomes of Bloodstream Infection with Extended-Spectrum β-Lactamase-Producing
    Xiao Y; Hang Y; Chen Y; Fang X; Cao X; Hu X; Luo H; Zhu H; Zhu W; Zhong Q; Hu L
    Infect Drug Resist; 2020; 13():4289-4296. PubMed ID: 33262623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk Factors for Extended-Spectrum-β-Lactamase-Producing
    Baek YJ; Kim YA; Kim D; Shin JH; Uh Y; Shin KS; Shin JH; Jeong SH; Lee GW; Lee EJ; Kim DS; Park YS
    Ann Lab Med; 2021 Sep; 41(5):455-462. PubMed ID: 33824233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Predictors and Mortality Between Bloodstream Infections Caused by ESBL-Producing Escherichia coli and ESBL-Producing Klebsiella pneumoniae.
    Scheuerman O; Schechner V; Carmeli Y; Gutiérrez-Gutiérrez B; Calbo E; Almirante B; Viale PL; Oliver A; Ruiz-Garbajosa P; Gasch O; Gozalo M; Pitout J; Akova M; Peña C; Molina J; Hernández-Torres A; Venditti M; Prim N; Origüen J; Bou G; Tacconelli E; Tumbarello M; Hamprecht A; Karaiskos I; de la Calle C; Pérez F; Schwaber MJ; Bermejo J; Lowman W; Hsueh PR; Navarro-San Francisco C; Bonomo RA; Paterson DL; Pascual A; Rodríguez-Baño J;
    Infect Control Hosp Epidemiol; 2018 Jun; 39(6):660-667. PubMed ID: 29618394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for bloodstream infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: A focus on antimicrobials including cefepime.
    Chopra T; Marchaim D; Johnson PC; Chalana IK; Tamam Z; Mohammed M; Alkatib S; Tansek R; Chaudhry K; Zhao JJ; Pogue JM; Kaye KS
    Am J Infect Control; 2015 Jul; 43(7):719-23. PubMed ID: 25934068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fecal ESBL Escherichia coli carriage as a risk factor for bacteremia in patients with hematological malignancies.
    Cornejo-Juárez P; Suárez-Cuenca JA; Volkow-Fernández P; Silva-Sánchez J; Barrios-Camacho H; Nájera-León E; Velázquez-Acosta C; Vilar-Compte D
    Support Care Cancer; 2016 Jan; 24(1):253-259. PubMed ID: 26014616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bloodstream infection due to extended-spectrum beta-lactamase (ESBL)-positive K. pneumoniae and E. coli: an analysis of the disease burden in a large cohort.
    Leistner R; Gürntke S; Sakellariou C; Denkel LA; Bloch A; Gastmeier P; Schwab F
    Infection; 2014 Dec; 42(6):991-7. PubMed ID: 25100555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors and outcomes in non-transplant patients with extended-spectrum beta-lactamase-producing
    Xiao T; Yang K; Zhou Y; Zhang S; Ji J; Ying C; Shen P; Xiao Y
    Antimicrob Resist Infect Control; 2019; 8():144. PubMed ID: 31467670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characteristics and outcome of critically ill patients with bacteremia caused by extended-spectrum β-lactamase-producing and non-producing Escherichia coli.
    Haruki Y; Hagiya H; Haruki M; Sugiyama T
    J Infect Chemother; 2018 Nov; 24(11):944-947. PubMed ID: 29803763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Impact of extended-spectrum β-lactamase on clinical outcome and medical cost in patients with bloodstream infection due to Klebsiella pneumoniae].
    Li JQ; Tang CQ; Wang H; Ji SZ; Lü KY; Xiao SC; Deng AM; Huang Y; Xia ZF
    Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(24):1903-6. PubMed ID: 27373357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiology and Burden of Bloodstream Infections Caused by Extended-Spectrum Beta-Lactamase Producing Enterobacteriaceae in a Pediatric Hospital in Senegal.
    Ndir A; Diop A; Faye PM; Cissé MF; Ndoye B; Astagneau P
    PLoS One; 2016; 11(2):e0143729. PubMed ID: 26867226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular analysis and risk factors for Escherichia coli producing extended-spectrum β-lactamase bloodstream infection in hematological malignancies.
    Cornejo-Juárez P; Pérez-Jiménez C; Silva-Sánchez J; Velázquez-Acosta C; González-Lara F; Reyna-Flores F; Sánchez-Pérez A; Volkow-Fernández P
    PLoS One; 2012; 7(4):e35780. PubMed ID: 22540004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Burden of bloodstream infection caused by extended-spectrum β-lactamase-producing enterobacteriaceae determined using multistate modeling at a Swiss University Hospital and a nationwide predictive model.
    Stewardson A; Fankhauser C; De Angelis G; Rohner P; Safran E; Schrenzel J; Pittet D; Harbarth S
    Infect Control Hosp Epidemiol; 2013 Feb; 34(2):133-43. PubMed ID: 23295559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcome of
    Zhang Q; Gao HY; Li D; Li Z; Qi SS; Zheng S; Bai CS; Zhang SH
    Infect Drug Resist; 2019; 12():359-371. PubMed ID: 30809097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective analysis of risk factors and outcomes in patients with extended-spectrum beta-lactamase-producing Escherichia coli bloodstream infections.
    Xiao T; Wu Z; Shi Q; Zhang X; Zhou Y; Yu X; Xiao Y
    J Glob Antimicrob Resist; 2019 Jun; 17():147-156. PubMed ID: 30634054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors, outcome and impact of empirical antimicrobial treatment in extended-spectrum β-lactamase-producing Escherichia coli bacteraemia.
    Van Aken S; Lund N; Ahl J; Odenholt I; Tham J
    Scand J Infect Dis; 2014 Nov; 46(11):753-62. PubMed ID: 25195648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Chopra T; Marchaim D; Veltman J; Johnson P; Zhao JJ; Tansek R; Hatahet D; Chaudhry K; Pogue JM; Rahbar H; Chen TY; Truong T; Rodriguez V; Ellsworth J; Bernabela L; Bhargava A; Yousuf A; Alangaden G; Kaye KS
    Antimicrob Agents Chemother; 2012 Jul; 56(7):3936-42. PubMed ID: 22547616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular detection of bla
    Son TV; Manh ND; Trung NT; Quyen DT; Meyer CG; Phuong NTK; Hoan PQ; Sang VV; Nurjadi D; Velavan TP; Bang MH; Song LH
    Ann Clin Microbiol Antimicrob; 2021 Sep; 20(1):60. PubMed ID: 34481499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular epidemiology and clinical features of extended-spectrum beta-lactamase- or carbapenemase-producing Escherichia coli bacteremia in Japan.
    Komatsu Y; Kasahara K; Inoue T; Lee ST; Muratani T; Yano H; Kirita T; Mikasa K
    PLoS One; 2018; 13(8):e0202276. PubMed ID: 30157275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.